Amundi Grows Position in IQVIA Holdings Inc. $IQV

Amundi grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 46.3% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 1,279,817 shares of the medical research company’s stock after buying an additional 405,250 shares during the period. Amundi’s holdings in IQVIA were worth $210,722,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in IQV. Verdence Capital Advisors LLC bought a new position in IQVIA in the 2nd quarter worth $3,612,000. Act Two Investors LLC bought a new position in shares of IQVIA in the second quarter worth about $26,528,000. Patton Fund Management Inc. bought a new stake in IQVIA during the 2nd quarter valued at approximately $231,000. Shell Asset Management Co. lifted its holdings in IQVIA by 78.7% in the 2nd quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company’s stock worth $1,459,000 after purchasing an additional 4,077 shares in the last quarter. Finally, Heritage Investors Management Corp grew its holdings in IQVIA by 10.5% during the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after buying an additional 9,909 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 0.3%

NYSE IQV opened at $225.68 on Friday. The stock has a market cap of $38.43 billion, a PE ratio of 30.96, a PEG ratio of 2.53 and a beta of 1.37. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The company’s 50-day moving average price is $214.48 and its 200-day moving average price is $186.71. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

IQV has been the subject of a number of research reports. Redburn Partners set a $214.00 target price on shares of IQVIA in a research report on Wednesday, September 3rd. Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Truist Financial reaffirmed a “buy” rating and issued a $265.00 target price (up from $235.00) on shares of IQVIA in a report on Wednesday, October 29th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, TD Cowen cut IQVIA from a “buy” rating to a “hold” rating and upped their price objective for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $241.44.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.